probucol has been researched along with Body Weight in 41 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effects of long-term treatment with probucol, a hypolipidemic agent with antioxidative action, insulin, or their combination on cataracts of streptozotocin-induced diabetic rats fed a high cholesterol diet." | 7.73 | Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet. ( Ito, M; Kimura, H; Kyuki, K; Yoshida, M, 2005) |
| " The aims of the present study were to investigate whether (a) dietary phytosterols reduce probucol-induced atherogenesis and (b) beneficial interactions exist between these agents." | 7.73 | Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. ( Moghadasian, MH, 2006) |
| "We examined the effect of probucol, a lipid-lowering agent with strong antioxidant properties, on neurological events and survival in stroke-prone spontaneously hypertensive rats (SHRSP)." | 7.70 | Failure of probucol to prolong survival in salt-loaded stroke-prone spontaneously hypertensive rats. ( Fujimura, A; Kawaguchi, A; Kitoh, Y; Miyashita, F; Sugimoto, K; Tsutsumi, H, 2000) |
| "We investigated the effects of long-term treatment with probucol, a hypolipidemic agent with antioxidative action, insulin, or their combination on cataracts of streptozotocin-induced diabetic rats fed a high cholesterol diet." | 3.73 | Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet. ( Ito, M; Kimura, H; Kyuki, K; Yoshida, M, 2005) |
| " The aims of the present study were to investigate whether (a) dietary phytosterols reduce probucol-induced atherogenesis and (b) beneficial interactions exist between these agents." | 3.73 | Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. ( Moghadasian, MH, 2006) |
| "Rats were either administered freshly prepared garlic homogenate (250 and 500 mg/kg daily, orally, for 30 days) or probucol (cumulative dose, 120 mg/kg body weight divided in 12, i." | 3.72 | Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. ( Banerjee, SK; Dinda, AK; Maulik, M; Maulik, SK; Mukherjee, S; Talwar, KK, 2003) |
| "We examined the effect of probucol, a lipid-lowering agent with strong antioxidant properties, on neurological events and survival in stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.70 | Failure of probucol to prolong survival in salt-loaded stroke-prone spontaneously hypertensive rats. ( Fujimura, A; Kawaguchi, A; Kitoh, Y; Miyashita, F; Sugimoto, K; Tsutsumi, H, 2000) |
| "Cataract formation occurred after 13 weeks in diabetic animals compared with 17 weeks for those treated with aminoguanidine, and 16 weeks for those treated with probucol (p < 0." | 3.70 | Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. ( Agardh, C; Agardh, E; Hultberg, B, 2000) |
| "Probucol treatment increased plasma SOD, decreased plasma MDA and improved hypoinsulinaemia in diabetic rats." | 1.37 | Possible role for the thioredoxin system in the protective effects of probucol in the pancreatic islets of diabetic rats. ( Lin, HL; Liu, DF; Liu, JH; Mei, X; Wang, NN, 2011) |
| "Treatment with probucol alone increased GSHPx activity at 2 weeks, and in these hearts, lipid peroxidation was lower than the control value." | 1.31 | Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. ( Li, T; Singal, PK, 2000) |
| "Probucol, a drug commonly employed for treatment of hypercholesterolemia, has antioxidant properties and inhibits oxidation of low density lipoproteins in vitro." | 1.30 | Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits. ( Fukai, T; Harrison, DG; Inoue, N; Nishida, K; Ohara, Y, 1998) |
| "Melatonin and probucol were equally effective in inhibiting the increase in myocardial TBARS as well as zinc levels, suggesting that myocardial zinc accumulation might be a protective response against adriamycin-induced oxidative stress." | 1.30 | Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant. ( Hayakawa, M; Hayakawa, T; Ito, T; Kaneko, S; Kawakami, K; Matsui, H; Mokuno, S; Morishima, I; Numaguchi, Y; Okumura, K; Toki, Y, 1999) |
| "Probucol prevented the increase in lipid peroxides, but had no effect on plasma cholesterol." | 1.29 | Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol. ( Cohen, RA; Haudenschild, CC; Simon, BC, 1993) |
| "Probucol treatment was associated a threefold increase in LDL resistance to copper-induced oxidative modification (P < 0." | 1.29 | Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. ( Cunningham, D; Frei, B; Jackson, T; Keaney, JF; Vita, JA; Xu, A, 1995) |
| "Primaquine treatment did not affect diabetic rats." | 1.29 | Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. ( Archibald, V; Cameron, NE; Cotter, MA; Dines, KC; Maxfield, EK, 1994) |
| "Probucol treatment had no effect on the cardiac performance of the nondiabetic control rats." | 1.28 | Effects of probucol on impaired cardiac performance and lipid metabolism in streptozotocin-induced diabetic rats. ( Kutsumi, Y; Miyabo, S; Nakai, T; Oida, K; Shimada, Y; Tada, H, 1992) |
| "Probucol is a bisphenolic compound that lowers serum cholesterol and also has potent antioxidant properties." | 1.28 | Effects of probucol in renal function and structure in rats with subtotal kidney ablation. ( Klahr, S; Modi, KS; Purkerson, ML; Schreiner, GF, 1992) |
| "Clofibrate treatment resulted in a reduction of plasma cholesterol, hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities." | 1.26 | Effect of probucol on cholesterol metabolism in the rat. ( Holets, RJ; Kottke, BA; Li, JR, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (24.39) | 18.7374 |
| 1990's | 19 (46.34) | 18.2507 |
| 2000's | 10 (24.39) | 29.6817 |
| 2010's | 2 (4.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, LL | 1 |
| Zhang, KQ | 1 |
| Tian, T | 1 |
| Zhang, H | 1 |
| Fu, Q | 1 |
| Liu, JH | 1 |
| Liu, DF | 1 |
| Wang, NN | 1 |
| Lin, HL | 1 |
| Mei, X | 1 |
| Mukherjee, S | 1 |
| Banerjee, SK | 1 |
| Maulik, M | 1 |
| Dinda, AK | 1 |
| Talwar, KK | 1 |
| Maulik, SK | 1 |
| Yoshida, M | 2 |
| Kimura, H | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Jeon, SM | 1 |
| Park, YB | 1 |
| Kwon, OS | 1 |
| Huh, TL | 1 |
| Lee, WH | 1 |
| Do, KM | 1 |
| Park, T | 1 |
| Choi, MS | 1 |
| Moghadasian, MH | 1 |
| Hong, SC | 1 |
| Zhao, SP | 1 |
| Wu, ZH | 1 |
| Delaigle, AM | 1 |
| Senou, M | 1 |
| Guiot, Y | 1 |
| Many, MC | 1 |
| Brichard, SM | 1 |
| Miettinen, TA | 1 |
| Huttunen, JK | 1 |
| Ehnholm, C | 1 |
| Kumlin, T | 1 |
| Mattila, S | 1 |
| Naukkarinen, V | 1 |
| Duarte, GM | 1 |
| Lavall, M | 1 |
| Li, JR | 1 |
| Holets, RJ | 1 |
| Kottke, BA | 1 |
| Barnard, SD | 1 |
| Molello, JA | 2 |
| Caldwell, WJ | 1 |
| Lebeau, JE | 1 |
| Zarkovic, M | 1 |
| Qin, X | 1 |
| Nakatsuru, Y | 1 |
| Zhang, S | 1 |
| Yamazaki, Y | 1 |
| Oda, H | 1 |
| Ishikawa, T | 2 |
| Simon, BC | 1 |
| Haudenschild, CC | 1 |
| Cohen, RA | 1 |
| Shand, JH | 1 |
| West, DW | 1 |
| Yamasaki, K | 1 |
| Yoshikawa, Y | 1 |
| Keaney, JF | 1 |
| Xu, A | 1 |
| Cunningham, D | 1 |
| Jackson, T | 1 |
| Frei, B | 1 |
| Vita, JA | 1 |
| Soulis-Liparota, T | 1 |
| Cooper, ME | 1 |
| Dunlop, M | 1 |
| Jerums, G | 1 |
| Cameron, NE | 1 |
| Cotter, MA | 1 |
| Archibald, V | 1 |
| Dines, KC | 1 |
| Maxfield, EK | 1 |
| Yoshino, G | 2 |
| Matsushita, M | 2 |
| Maeda, E | 1 |
| Nagata, K | 1 |
| Naka, Y | 1 |
| Murata, Y | 1 |
| Hirano, T | 1 |
| Kazumi, T | 2 |
| LeBlanc, GA | 1 |
| Gillette, JS | 1 |
| Bravo, E | 1 |
| Ortu, G | 1 |
| Rivabene, R | 1 |
| Santini, MT | 1 |
| Cantafora, A | 1 |
| Fruebis, J | 2 |
| Bird, DA | 1 |
| Pattison, J | 1 |
| Palinski, W | 2 |
| Palmer, AM | 1 |
| Gopaul, N | 1 |
| Dhir, S | 1 |
| Thomas, CR | 1 |
| Poston, L | 1 |
| Tribe, RM | 1 |
| Inoue, N | 1 |
| Ohara, Y | 1 |
| Fukai, T | 1 |
| Harrison, DG | 1 |
| Nishida, K | 1 |
| Oshima, R | 1 |
| Ikeda, T | 1 |
| Watanabe, K | 1 |
| Itakura, H | 1 |
| Sugiyama, N | 1 |
| Morishima, I | 1 |
| Okumura, K | 1 |
| Matsui, H | 1 |
| Kaneko, S | 1 |
| Numaguchi, Y | 1 |
| Kawakami, K | 1 |
| Mokuno, S | 1 |
| Hayakawa, M | 1 |
| Toki, Y | 1 |
| Ito, T | 1 |
| Hayakawa, T | 1 |
| Silvestre, M | 1 |
| Shelton, D | 1 |
| Napoli, C | 1 |
| Miyashita, F | 1 |
| Kawaguchi, A | 1 |
| Sugimoto, K | 1 |
| Kitoh, Y | 1 |
| Tsutsumi, H | 1 |
| Fujimura, A | 1 |
| Agardh, E | 1 |
| Hultberg, B | 1 |
| Agardh, C | 1 |
| Li, T | 1 |
| Singal, PK | 1 |
| Yoshida, N | 1 |
| Murase, H | 1 |
| Kunieda, T | 1 |
| Toyokuni, S | 1 |
| Tanaka, T | 1 |
| Terao, J | 1 |
| Naito, Y | 1 |
| Tanigawa, T | 1 |
| Yoshikawa, T | 1 |
| Nash, DT | 1 |
| Tada, H | 1 |
| Oida, K | 1 |
| Kutsumi, Y | 1 |
| Shimada, Y | 1 |
| Nakai, T | 1 |
| Miyabo, S | 1 |
| Modi, KS | 1 |
| Schreiner, GF | 1 |
| Purkerson, ML | 1 |
| Klahr, S | 1 |
| Staels, B | 1 |
| van Tol, A | 1 |
| Jansen, H | 1 |
| Auwerx, J | 1 |
| Morel, DW | 1 |
| Chisolm, GM | 1 |
| Iwai, M | 1 |
| Matsuba, K | 1 |
| Morita, M | 1 |
| Iwatani, I | 1 |
| Baba, S | 1 |
| Gerbig, CG | 1 |
| Robinson, VB | 1 |
| Polachek, AA | 1 |
| Katz, HM | 1 |
| Sack, J | 1 |
| Selig, J | 1 |
| Littman, ML | 1 |
| Brown, HB | 1 |
| De Wolfe, VG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for probucol and Body Weight
| Article | Year |
|---|---|
Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
Topics: Antihypertensive Agents; Apolipoproteins; Body Weight; Cholesterol; Clofibrate; Humans; Hyperlipopro | 1980 |
Probucol in the long-term treatment of hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Drug Hypersensi | 1973 |
The additive effect of probucol on diet in hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Diet Ther | 1974 |
38 other studies available for probucol and Body Weight
| Article | Year |
|---|---|
Probucol improves erectile function via Activation of Nrf2 and coordinates the HO-1 / DDAH / PPAR-γ/ eNOS pathways in streptozotocin-induced diabetic rats.
Topics: Amidohydrolases; Animals; Arginine; Blood Glucose; Body Weight; Cyclic GMP; Diabetes Mellitus, Exper | 2018 |
Possible role for the thioredoxin system in the protective effects of probucol in the pancreatic islets of diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Carrier Proteins; Cell Cycle Proteins; Control Gr | 2011 |
Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression.
Topics: Animals; Antioxidants; Body Weight; Cardiomyopathies; Catalase; Doxorubicin; Garlic; Gene Expression | 2003 |
Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet.
Topics: Animals; Blood Glucose; Body Weight; Cataract; Cholesterol; Cholesterol, Dietary; Diabetes Mellitus, | 2005 |
Vitamin E supplementation alters HDL-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Aorta; Aryldialkylphosphatase; Aspartate Am | 2005 |
Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Body Weight; Cholesterol; Cho | 2006 |
Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Body Weight; Gene Expressio | 2006 |
Induction of adiponectin in skeletal muscle of type 2 diabetic mice: In vivo and in vitro studies.
Topics: Adiponectin; Animals; Antioxidants; Body Weight; Cells, Cultured; Diabetes Mellitus, Type 2; DNA Pri | 2006 |
[Effects of probucol on plasma cholesterol and triglyceride levels].
Topics: Adult; Body Weight; Chemical Phenomena; Chemistry; Cholesterol; Hemodynamics; Humans; Hypercholester | 1981 |
Effect of probucol on cholesterol metabolism in the rat.
Topics: Animals; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Hydroxymethylglutary | 1980 |
[Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
Topics: Animals; Body Weight; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Liver; Microbodies; Mic | 1980 |
Inhibitory effect of probucol on benzo[a]pyrene induced lung tumorigenesis.
Topics: Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Benzo(a)pyrene; Body Weight; Carcinogens | 1995 |
Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Body Weight; Calcimycin; Cholesterol; Coronary Artery Disea | 1993 |
The effects of probucol and clofibrate alone and in combination on hepatic cholesterol metabolism in the male rat.
Topics: Animals; Body Weight; Cholesterol; Clofibrate; Cytosol; Lipid Metabolism; Lipids; Liver; Male; Micro | 1995 |
Effect of a lipid-lowering agent or a high-cholesterol diet on focal glomerulosclerosis in hyperlipidemic rats.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Glomerulosclerosis, Focal Segmental; Hyperl | 1995 |
Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.
Topics: Animals; Antioxidants; Arteries; Arteriosclerosis; Body Weight; Cholesterol; Diet, Atherogenic; Endo | 1995 |
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Topics: Albuminuria; Aldehyde Reductase; Animals; Antioxidants; Blood Glucose; Body Weight; Butylated Hydrox | 1995 |
Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; Motor Neurons; | 1994 |
Effect of long-term administration of probucol on triglyceride turnover in rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol, VLDL; Insulin; Lipids; Male; Polyethylene Glycols; | 1994 |
Elevation of serum cholesterol levels in mice by the antioxidant butylated hydroxyanisole.
Topics: Animals; Antioxidants; Body Weight; Butylated Hydroxyanisole; Cholesterol; Cholesterol, Dietary; Mal | 1993 |
Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats.
Topics: Animals; Anticholesteremic Agents; Bile; Body Weight; Cholesterol; Cholesterol Esters; Cholesterol, | 1996 |
Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants.
Topics: Animals; Antioxidants; Arteriosclerosis; Body Weight; Cholesterol; Lipid Peroxidation; Lipoproteins, | 1997 |
Endothelial dysfunction in streptozotocin-diabetic rats is not reversed by dietary probucol or simvastatin supplementation.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet; Dinoprost; | 1998 |
Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol, Dietary; Endothelium, Vascular; Hyperch | 1998 |
Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Topics: Actins; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arter | 1998 |
Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant.
Topics: Animals; Antioxidants; Ascites; Body Weight; Cardiomyopathies; Doxorubicin; Heart Ventricles; Lipid | 1999 |
Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits.
Topics: Animals; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Copper; | 1999 |
Failure of probucol to prolong survival in salt-loaded stroke-prone spontaneously hypertensive rats.
Topics: Animals; Anticholesteremic Agents; Blood Pressure; Body Weight; Hypertension; Male; Probucol; Rats; | 2000 |
Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cataract; Cysteine; Diabetes Mellitus, Experimental; Diabetic R | 2000 |
Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Body Weight; Catalase; Doxorubicin; Drug Interactio | 2000 |
Inhibitory effect of a novel water-soluble vitamin E derivative on atherosclerosis in rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta; Arteriosclerosis; Aspartate Aminotransferases; B | 2002 |
[Hypolipidemic effects of DH581 during prolonged administration (author's transl)].
Topics: Adolescent; Adult; Aged; Body Weight; Cholesterol; Drug Evaluation; Female; Humans; Hypercholesterol | 1976 |
Effects of probucol on impaired cardiac performance and lipid metabolism in streptozotocin-induced diabetic rats.
Topics: Animals; Biological Transport, Active; Blood Glucose; Body Weight; Calcium; Cardiac Output; Chromato | 1992 |
Effects of probucol in renal function and structure in rats with subtotal kidney ablation.
Topics: Animals; Atrophy; Blood Pressure; Body Weight; Cholesterol; Female; Fibrosis; Hematocrit; Kidney; Ki | 1992 |
The effects of probucol on lipoprotein metabolism in the rat.
Topics: Animals; Apolipoproteins; Blotting, Northern; Body Weight; Cholesterol; Energy Intake; Intestinal Mu | 1991 |
Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cell Survival; Cells, Cultured; Diabetes Mellitus | 1989 |
Protective effect of probucol on alloxan diabetes in rats.
Topics: Alloxan; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glycosuria; Islets of | 1989 |
Toxicity of (4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol)), probucol, in mice, rats, dogs and monkeys: demonstration of a species-specific phenomenon.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Diet; Dogs; Female; Haplorhini; Lethal | 1973 |